This trial is active, not recruiting.

Conditions retinoblastoma, retinal neoplasms
Treatments carboplatin, vp-16, local surgery, cryotherapy, laser hyperthermia
Phase phase 2
Sponsor Ann & Robert H Lurie Children's Hospital of Chicago
Start date April 1996
End date September 2006
Trial size 30 participants
Trial identifier NCT00179920, CNS 0294


Retinoblastoma is an unusual cancer of early childhood involving tumor is both eyes or, in certain circumstances, one eye only. This condition is the result of an abnormal gene which makes both retinas (the back of the eye) vulnerable to develop multiple tumors. Growths in the eye impair vision temporarily or permanently. These tumors are malignant, which means that they can grow within the eye, spread outside of the eye, and be fatal if untreated.

Standard therapy for bilateral retinoblastoma includes removal of one eye if vision cannot be save and radiation treatment of either eye in which vision might be saved. Radiation controls tumor growth in the majority of cases. Another standard method is cryotherapy (freezing a tumor to kill it). Chemotherapy (medicines used to kill tumor cells) has been used in the past for tumor in or outside the eye, but is not standard. Hyperthermia, increasing the temperature of a tumor to kill it, is widely performed, and can be done to a retinoblastoma tumor by a laser; this method is not standard.

The problem with removal of an eye is that any hope of vision is lost. The problems with radiation include incomplete control of tumor, injury to the eye or surrounding tissue with decreased growth, and that (due to the abnormal retinoblastoma gene) children are very susceptible to develop other tumors, especially in the tissue which was given radiation.

The doctors at Children's Memorial Hospital are using a newer form of treatment, including laser hyperthermia, chemotherapy and cryotherapy to decrease retinoblastoma tumors. Some may be controlled indefinitely, reducing the number of eyes that need radiation or removal.


1. To find out how well chemotherapy plus cryotherapy and laser hyperthermia work on retinoblastoma tumors.

2. To find out whether vision can be saved and tumors controlled without radiation or removal of the eye.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment

Primary Outcomes

To determine if a multimodal approach can provide durable control of retinoblastoma and specifically:
time frame:
Estimate the proportion of eyes in which radiation therapy can be omitted
time frame:
Estimate the proportion of eyes in which vision can be retained
time frame:

Secondary Outcomes

To estimate the response rate and duration for primary retinoblastoma tumors to combination therapy with carboplatin and VP-16
time frame:
To estimate the response rate of qualifying in situ retinoblastoma tumors to local surgical therapies, specifically estimate tumor response and duration after laser hyperthermia concurrent with carboplatin
time frame:
Estimate tumor response and duration after cryotherapy
time frame:
To estimate the control rate of vitreous involvement by retinoblastoma to carboplatin and VP-16
time frame:
To detect any toxicities resulting from multimodal therapy plus local surgical options
time frame:

Eligibility Criteria

Male or female participants of any age.

Eligibility Criteria: - Initial clinical diagnosis of Retinoblastoma, with Bilateral tumors, OR Unilateral tumor with hope for salvage of vision AND Multiple primary tumors, or positive family history for retinoblastoma, or age < 12 months - No prior antitumor therapy (except enucleation of one eye) - At least one tumor exceeds 6 mm in diameter - No evidence of dissemination outside the globe - Signed IRB-approved informed consent - Patient/family available for follow-up

Additional Information

Official title Chemotherapy Plus Local Surgical Treatment in Children With Intraocular Germ-Line Retinoblastoma
Principal investigator Stewart Goldman, MD
Trial information was received from ClinicalTrials.gov and was last updated in September 2012.
Information provided to ClinicalTrials.gov by Ann & Robert H Lurie Children's Hospital of Chicago.